PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily.

This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Clinical diagnosis of diffuse large B cell lymphoma

• Recently completed R-CHOP therapy and achieved remission

• International Prognostic Index (IPI) score 3,4,5

• At least 18 years of age

• Agree to study follow-up schedule

Exclusion Criteria:

• Have received therapy other than R-CHOP for lymphoma

• Serious medical condition such as infection,second cancer,heart disease

• Received radiation to more than one lesion

• Unable to swallow tablets